{"id":"faropenem","rwe":[{"pmid":"41169285","year":"2025","title":"A post-surgical case of rib osteomyelitis and pleural abscess caused by mycobacterium abscessus after 6 years of lung cancer surgery.","finding":"","journal":"Oxford medical case reports","studyType":"Clinical Study"},{"pmid":"41146779","year":"2025","title":"Pyometra by Clostridium clostridioforme: A Case Report.","finding":"","journal":"Cureus","studyType":"Clinical Study"},{"pmid":"41020898","year":"2025","title":"Anti-TB Drugs for Drug-Sensitive and Drug-Resistant Mycobacterium tuberculosis: A Review.","finding":"","journal":"Current issues in molecular biology","studyType":"Clinical Study"},{"pmid":"41002148","year":"2025","title":"Oral β-lactam combinations are effective in vitro against Mycobacterium avium, regardless of clarithromycin susceptibility.","finding":"","journal":"Microbiology spectrum","studyType":"Clinical Study"},{"pmid":"40952390","year":"2025","title":"Targeting mycobacterial transpeptidases: evaluating the roles of Ldt and PBP inhibition in suppressing Mycobacterium smegmatis.","finding":"","journal":"Antimicrobial agents and chemotherapy","studyType":"Clinical Study"}],"tags":[{"label":"faropenem","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"J01DI03","category":"atc"},{"label":"Active","category":"status"},{"label":"Bacterial infection of skin","category":"indication"},{"label":"Respiratory tract infection","category":"indication"}],"phase":"phase_3","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"fropenem","offLabel":[],"synonyms":["faropenem sodium hydrate","fropenem","faropenem sodium","faropenem"],"timeline":[],"approvals":[],"brandName":"Fropenem","ecosystem":[{"indication":"Bacterial infection of skin","otherDrugs":[{"name":"chloramphenicol","slug":"chloramphenicol","company":"Parkedale"},{"name":"dalbavancin","slug":"dalbavancin","company":"Durata Theraps Intl"},{"name":"delafloxacin","slug":"delafloxacin","company":"Melinta Therapeutics Inc"},{"name":"gentamicin","slug":"gentamicin","company":"Schering"}],"globalPrevalence":null},{"indication":"Respiratory tract infection","otherDrugs":[],"globalPrevalence":890552}],"mechanism":{"modality":"Small Molecule","drugClass":"faropenem","explanation":"Imagine your body's cells are like houses, and bacteria are like unwanted guests. Faropenem helps to stop the bacteria from building new 'houses' by blocking the tools they need to do so, ultimately leading to their demise.","oneSentence":"Faropenem works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.","technicalDetail":"Faropenem exerts its antibacterial effect by inhibiting the enzyme transpeptidase, which is essential for bacterial cell wall synthesis, thereby preventing bacterial cell division and ultimately leading to bacterial cell death."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1131","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=FAROPENEM","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FAROPENEM","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:13:06.700120","biosimilars":[],"competitors":[{"drugName":"ceftaroline fosamil","drugSlug":"ceftaroline-fosamil","fdaApproval":"2010-10-29","patentExpiry":"Sep 21, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"cefiderocol","drugSlug":"cefiderocol","fdaApproval":"2019-11-14","patentExpiry":"Sep 3, 2035","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ceftolozane","drugSlug":"ceftolozane","fdaApproval":"2014-12-19","relationship":"same-class"}],"genericName":"faropenem","indications":{"approved":[{"name":"Bacterial infection of skin","source":"DrugCentral","snomedId":128936008,"regulator":"FDA"},{"name":"Respiratory tract infection","source":"DrugCentral","snomedId":275498002,"regulator":"FDA","usPrevalence":null,"globalPrevalence":890552,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (ORPHANET)"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"ceftaroline-fosamil","brandName":"ceftaroline fosamil","genericName":"ceftaroline fosamil","approvalYear":"2010","relationship":"same-class"},{"drugId":"cefiderocol","brandName":"cefiderocol","genericName":"cefiderocol","approvalYear":"2019","relationship":"same-class"},{"drugId":"ceftolozane","brandName":"ceftolozane","genericName":"ceftolozane","approvalYear":"2014","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06804096","phase":"PHASE4","title":"Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP)","status":"RECRUITING","sponsor":"Dr. Md. Alimur Reza","startDate":"2025-02-20","conditions":["Pneumonia, Community-Acquired","Bacterial Pneumonia"],"enrollment":160,"completionDate":"2025-12-01"},{"nctId":"NCT02381470","phase":"PHASE2","title":"Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers","status":"COMPLETED","sponsor":"National University Hospital, Singapore","startDate":"2019-02-11","conditions":["Pulmonary Tuberculosis"],"enrollment":58,"completionDate":"2019-10-02"},{"nctId":"NCT02349841","phase":"PHASE2","title":"Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"TASK Applied Science","startDate":"2014-09","conditions":["Pulmonary Tuberculosis"],"enrollment":46,"completionDate":"2014-12"},{"nctId":"NCT02393586","phase":"PHASE1","title":"Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Faropenem Plus Amoxicillin/Clavulanic Acid in Healthy Volunteers","status":"COMPLETED","sponsor":"National University Hospital, Singapore","startDate":"2015-02","conditions":["Tuberculosis"],"enrollment":43,"completionDate":"2015-10"},{"nctId":"NCT01937832","phase":"PHASE3","title":"A Phase III Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2013-10","conditions":["Community Acquired Pneumonia"],"enrollment":540,"completionDate":""},{"nctId":"NCT01886053","phase":"PHASE2","title":"A Phase II Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2011-04","conditions":["Community Acquired Pneumonia"],"enrollment":189,"completionDate":"2012-07"},{"nctId":"NCT00255983","phase":"PHASE3","title":"A Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil In the Treatment of Chronic Bronchitis","status":"TERMINATED","sponsor":"Replidyne","startDate":"2005-12","conditions":["Chronic Bronchitis"],"enrollment":491,"completionDate":"2008-06"},{"nctId":"NCT00276042","phase":"PHASE2","title":"A Trial to Evaluate Faropenem Medoxomil in the Treatment of Acute Otitis Media","status":"COMPLETED","sponsor":"Replidyne","startDate":"2006-01","conditions":["Otitis Media"],"enrollment":328,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"F52Y83BGH3","CHEBI":"CHEBI:51257","INN_ID":"7086","UMLSCUI":"C0541153","ChEMBL_ID":"CHEMBL556262","KEGG_DRUG":"D01839","DRUGBANK_ID":"DB12190","PDB_CHEM_ID":" FPM","PUBCHEM_CID":"65894","SNOMEDCT_US":"1162766006","IUPHAR_LIGAND_ID":"10808","SECONDARY_CAS_RN":"122547-49-3","MESH_SUPPLEMENTAL_RECORD_UI":"C107057"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"1.4 hours","clearance":"2.23 mL/min/kg","volumeOfDistribution":"0.18 L/kg"},"publicationCount":231,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"J01DI03","allCodes":["J01DI03"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Oct","pmid":"41169285","title":"A post-surgical case of rib osteomyelitis and pleural abscess caused by mycobacterium abscessus after 6 years of lung cancer surgery.","journal":"Oxford medical case reports"},{"date":"2025 Sep","pmid":"41146779","title":"Pyometra by Clostridium clostridioforme: A Case Report.","journal":"Cureus"},{"date":"2025 Sep 19","pmid":"41020898","title":"Anti-TB Drugs for Drug-Sensitive and Drug-Resistant Mycobacterium tuberculosis: A Review.","journal":"Current issues in molecular biology"},{"date":"2025 Nov 4","pmid":"41002148","title":"Oral β-lactam combinations are effective in vitro against Mycobacterium avium, regardless of clarithromycin susceptibility.","journal":"Microbiology spectrum"},{"date":"2025 Oct","pmid":"40952390","title":"Targeting mycobacterial transpeptidases: evaluating the roles of Ldt and PBP inhibition in suppressing Mycobacterium smegmatis.","journal":"Antimicrobial agents and chemotherapy"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fropenem, also known as Faropenem, is a small molecule antibiotic belonging to the faropenem class. It is used to treat bacterial infections of the skin and respiratory tract. The commercial status of Faropenem is unclear, but it is likely patented. Key safety considerations include its short half-life of 1.4 hours. Faropenem's exact target is unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}